Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Sees Large Increase in Short Interest

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) was the recipient of a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 79,000 shares, a growth of 101.5% from the March 31st total of 39,200 shares. Approximately 2.2% of the company’s stock are short sold. Based on an average daily volume of 206,900 shares, the days-to-cover ratio is currently 0.4 days.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on Galmed Pharmaceuticals in a research report on Wednesday. They issued a “sell” rating on the stock.

Galmed Pharmaceuticals Stock Performance

Shares of NASDAQ:GLMD remained flat at $0.39 during midday trading on Friday. The company had a trading volume of 27,223 shares, compared to its average volume of 260,258. Galmed Pharmaceuticals has a twelve month low of $0.26 and a twelve month high of $7.80. The company’s fifty day moving average is $0.36 and its 200 day moving average is $0.38.

Galmed Pharmaceuticals (NASDAQ:GLMD) last posted its earnings results on Thursday, April 4th. The biopharmaceutical company reported ($0.98) EPS for the quarter.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.